Background-The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes independently of its enzymatic activity the degradation of the low-density lipoprotein (LDL) receptor. PCSK9 gain of function in humans leads to autosomal dominant hypercholesterolemia, whereas the absence of functional PCSK9 results in Ϸ7-fold lower levels of LDL cholesterol. This suggests that lowering PCSK9 may protect against atherosclerosis. Methods and Results-We investigated the role of PCSK9 in atherosclerosis in C57BL/6 wild-type (WT), apolipoprotein E-deficient, and LDL receptor-deficient mouse models. Circulating cholesterol levels, fast protein liquid chromatography profiles, aortic cholesteryl esters (CE), and plaque sizes were determined. Intima-media thicknesses were measured by ultrasound biomicroscopy. First, mice expressing null (knockout [KO]), normal (WT), or high (transgenic [Tg]) levels of PCSK9 were fed a 12-month Western diet. KO mice accumulated 4-fold less aortic CE than WT mice, whereas Tg mice exhibited high CE and severe aortic lesions. Next we generated apolipoprotein E-deficient mice, known to spontaneously develop lesions, that expressed null (KO/e), normal (WT/e), or high (Tg/e) levels of PCSK9. After a 6-month regular diet, KO/e mice showed a 39% reduction compared with WT/e mice in aortic CE accumulation, whereas Tg/e mice showed a 137% increase. Finally, LDL receptor-deficient mice expressing no (KO/L), normal (WT/L), or high (Tg/L) levels of PCSK9 were fed a Western diet for 3 months. KO/L and Tg/L mice exhibited levels of plasma cholesterol and CE accumulation similar to those of WT/L mice, suggesting that PCSK9 modulates atherosclerosis mainly via the LDL receptor. Conclusions-Altogether, our results show a direct relationship between PCSK9 and atherosclerosis. PCSK9 overexpression is proatherogenic, whereas its absence is protective. (Circulation. 2012;125:894-901 .) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
A therosclerosis is a progressive degenerative pathology of large arteries that leads to ischemic heart diseases, which are expected to remain one of the leading causes of mortality until at least 2030. 1 The different stages of atherosclerotic plaque development have been reviewed extensively. [2] [3] [4] [5] In brief, high levels of circulating atherogenic lipoproteins favor the accumulation of oxidized low-density lipoproteins (LDLs) in the subendothelial space. The latter are taken up by invading macrophages that, if they cannot efflux excess cholesterol to high-density lipoprotein, become foam cells. Foamy cells then release cytokines that recruit more macrophages into the building plaque. After formation of a necrotic core, plaques may ultimately become unstable; their fibrous cap can rupture and cause the formation of thrombus that can lead to death. Although inflammation is an important contributor to atherosclerosis, accumulation of oxidized LDLs in the subendothelial compartment is a key triggering event in atherosclerosis. Lowering the levels of circulating atherogenic particles is thus a good approach to prevent cardiovascular diseases.
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Autosomal dominant hypercholesterolemia is a disorder of elevated plasma levels of LDL cholesterol (LDL-C) linked to dominant mutations occurring mostly in the gene encoding the LDL receptor (LDLR) and less frequently in that encoding apolipoprotein B. In 2003, a third locus involved in familial hypercholesterolemia was discovered, 6 the PCSK9 gene encoding the proprotein convertase subtilisin/kexin type 9 (PCSK9). 7 This serine protease belongs to the family of proprotein convertases (PCs) that cleave precursors of hormones, growth factors, receptors, or membrane-bound transcription factors (for review, see Seidah et al 8 ) . However, unlike the other PCs, PCSK9 has thus far no known substrate but itself. In the endoplasmic reticulum, it autocatalytically cleaves its prosegment, which remains noncovalently tightly bound to the protein. 7, 9 Several studies have now clearly established that PCSK9 regulates LDLR protein levels. In a complex with its prosegment, PCSK9 binds the LDLR and prevents recycling of the receptor to the cell surface, thereby promoting its degradation in lysosomes. 9 -11 A recent study suggests that PCSK9 binding maintains 3 contiguous domains of the LDLR (L7, repeat 7 of the ligand binding domain; EGF-A; EGF-B) in an extended conformation that is incompatible with LDLR recycling to the cell surface. 12 However, PCSK9 binding to the LDLR may also be regulated by other partners, namely, via interactions involving the cysteine-and histidine-rich C-terminal domain of PCSK9. 13 PCSK9 is highly expressed in the liver and is found in the plasma at concentrations of Ϸ100 to 200 ng/mL. 14, 15 Although PCSK9 is a key player in cholesterol homeostasis through the regulation of LDLR levels, circulating PCSK9 also plays a role in triglyceride metabolism by promoting the degradation of the very low-density lipoprotein (VLDL) receptor. 16 -18 In addition, PCSK9 promotes ex vivo the degradation of apolipoprotein ER2, 16, 17 which is also closely related to the LDLR.
Approximately 2% to 3% of patients with autosomal dominant hypercholesterolemia carry mutations in PCSK9. Gain-of-function mutations of the human PCSK9 protein lead to higher circulating LDL-C and increased incidence of cardiovascular diseases. 19 The most severe mutation, which was reported in Norwegians 20 and Mormons from Utah 21 who exhibit cholesterol levels of Ϸ500 mg/dL, is the substitution of Asp 374 by Tyr (D374Y), which increases the affinity of PCSK9 for the LDLR by at least 10-fold. 22 Conversely, PCSK9 loss-of-function mutations lead to hypocholesterolemia. Interestingly, Ϸ2% of blacks carry a Y142X or C679X nonsense polymorphism in 1 PCSK9 allele 23 that reduces LDL-C by 40%. Moreover, the characterization of 2 women lacking functional PCSK9 and exhibiting Ϸ14 mg/dL (0.38 mmol/L) of LDL-C revealed that PCSK9 is not essential. 24, 25 Thus, PCSK9 appears to be a promising target to reduce LDL-C levels.
Statins inhibit cholesterol synthesis and increase LDLR expression in hepatocytes, thereby leading to increased hepatic LDL clearance from the circulation. However, statins concomitantly induce PCSK9 expression, 15, 26 which promotes the degradation of the LDLR and thus impairs the optimal LDLR-mediated LDL clearance. Thus, PCSK9 inhibition, alone or in combination with statins, has emerged as a potentially new approach to reduce circulating LDL.
In this study, we analyzed the impact of the absence or overexpression of PCSK9 on atherosclerosis in wellestablished mouse models. Our data demonstrate a direct relationship between PCSK9 and the development of atherosclerosis. The accumulation of cholesteryl esters (CE) in aortas was markedly reduced in mice lacking PCSK9 in both wild-type (WT) and atherogenic apolipoprotein E (apoE)deficient backgrounds. Conversely, PCSK9 overexpression severely worsened the atherosclerotic phenotypes. Finally, the process by which PCSK9 enhances atherosclerosis ap-pears to be mediated primarily through its action on the LDLR because LDLR-deficient mice lacking or overexpressing PCSK9 do not show significant differences in CE accumulation and plaque size.
Methods

Animals and Diets
All procedures were approved by the animal care committee of the Institut de recherches cliniques de Montréal. Pcsk9 Ϫ/Ϫ (knockout [KO]) mice, which lack the Pcsk9 proximal promoter and exon 1 region, and transgenic (Tg) mice, which express murine PCSK9 under the control of the apoE promoter, were described previously 27 and were since backcrossed 7 to 10 times to C57BL/6 mice. C57BL/6, Apoe Ϫ/Ϫ , 28 and Ldlr Ϫ/Ϫ 29 mice were obtained from the Jackson Laboratory. The latter were all in a C57BL/6 background. PCSK9 KO and Tg mice were crossed to Apoe Ϫ/Ϫ mice or Ldlr Ϫ/Ϫ mice to obtain Pcsk9 Ϫ/Ϫ Apoe Ϫ/Ϫ (KO/e) or Pcsk9 Ϫ/Ϫ Ldlr Ϫ/Ϫ (KO/L); Pcsk9 ϩ/ϩ Apoe Ϫ/Ϫ (WT/e) or Pcsk9 ϩ/ϩ Ldlr Ϫ/Ϫ (WT/L); and Tg(Pcsk9) ϩ/0 Apoe Ϫ/Ϫ (Tg/e) or Tg(Pcsk9) ϩ/0 Ldlr Ϫ/Ϫ (Tg/L) mice. All transgenic strains are hemizygous for the PCSK9 transgene. At 3 to 4 weeks of age, mice were weaned and fed a regular (2018 Teklad Global) or Western (TD.88137 Harlan Teklad) diet for 3, 6, or 12 months. The Western diet contained 34%, 21%, and 0.2% of sugar, fat, and cholesterol, respectively, whereas the regular diet contained 5%, 6%, and 0% of these ingredients. PCSK9 mRNA was quantified by reverse transcription quantitative polymerase chain reaction. 27 The levels of circulating PCSK9 and of total and surface LDLR in hepatocytes were assessed by enzyme-linked immunosorbent assay, Western blotting, and immunofluorescence, respectively. These results and corresponding methods can be found in Figure I 
Genotyping
Apoe, Ldlr, and Pcsk9 genotyping was performed by polymerase chain reaction amplification on genomic DNA isolated from mouse tails. Polymerase chain reaction products were then separated on a 3130Xl Genetic Analyzer (Applied Biosystems) and identified on the basis of fragment size and expected fluorescence, according to the manufacturer's instructions. For the V5-tagged PCSK9 transgene, 27 a quantitative polymerase chain reaction with the use of a TaqMan probe was performed in a ViiA7 quantitative polymerase chain reaction apparatus (Applied Biosystems) in accordance with the manufacturer's instructions. The primers used are presented in the 
Animal Euthanasia and Dissection
Mice were fasted for Ϸ4 hours before euthanasia. Under anesthesia with 2% isoflurane in oxygen, total bleed was performed by heart puncture with the use of a 21-gauge needle mounted on a 1-mL syringe. The right atrium was cut out, and the remaining blood was flushed by pump-monitored perfusion (0.4 mL/min) from the left ventricle with phosphate-buffered saline (PBS) for 10 minutes with the use of a 25-gauge butterfly needle mounted on a 20-mL syringe. Aortas were then perfused-fixed for 10 minutes with PBS containing 4% paraformaldehyde. Organs were weighed, and the aorta was roughly dissected from the heart down to the iliac branches and stored in 4% paraformaldehyde for 1 to 3 days. Finally, a fine dissection under a microscope further allowed removal of the adventitia before photography and lipid extraction.
Ultrasound Biomicroscopy
On the day of euthanasia, intima-media thickness (IMT) was determined by B-mode ultrasonography with a Vevo 770 apparatus (Visual Sonics, Toronto, Canada) equipped with a 30-MHz probe, 30 with a depth focus at 12.7 mm. Animals were maintained under anesthesia with 2% isoflurane in oxygen during the whole procedure. A hair remover (Nair) was used to clean the mouse chest, and a transmission gel was applied before scanning. Three-second cine-loop movies were recorded for further offline analysis. A left parasternal long-axis view was used to visualize the aortic valves, aortic root, and ascending aorta. A right parasternal short-axis view was used to visualize the aortic arch and brachiocephalic artery ( Figure II in the online-only Data Supplement). All measurements were performed at systole by an operator blinded for genotypes. The measurement at the level of the valves was taken as a perpendicular cross section directly in the middle of the valves; for the aortic root, the measurement was taken at the level of the coronary branches; for the ascending aorta, it was taken Ϸ1 mm away from the beginning of the aortic root; and for the brachiocephalic artery, the measurement was taken Ϸ0.5 mm away from the branching from the aortic arch. IMT was defined as follows: (outer diameterϪinner diameter)/2.
Plasma Cholesterol Analysis
Blood was stored on ice in Eppendorf tubes containing 15 L of 40 U/mL heparin, centrifuged at 3000 rpm for 20 minutes at 4°C, and the supernatant was frozen until further analysis. For fast protein liquid chromatography (FPLC) profiles, plasma samples from 5 to 10 mice were combined, and 400 L was loaded on a 10ϫ60-mm Superose 6 column eluted with 0.9% NaCl, pH 7.0, at a rate of 300 L/min in 96 fractions. Total cholesterol in the original plasma (4 L) or in FPLC fractions (125 or 75 L of 300 L for regular or Western diet, respectively) was determined with the use of the Infinity kit.
Aortic Lipid Extraction and CE Determination
The aorta was cut into small pieces with microscissors, crushed in 250 L PBS with homogenizers for Eppendorf tubes, and further homogenized by passing 20 times in a 25-gauge needle mounted on a 1-mL syringe. The volume was completed to 500 L with PBS, and the sample was sonicated 3ϫ10 seconds on ice. After transfer in a glass tube, 4.5 mL of methanol/chloroform (1:2) was added, and samples were incubated overnight with vigorous agitation. Samples were centrifuged at 1000g for 10 minutes, the aqueous (upper) phase was removed, the organic (lower) phase was transferred to a new glass tube and evaporated under a nitrogen atmosphere, and 450 L of 1% Triton X-100 in chloroform was added before final evaporation. Determination of CE levels was then performed as described 31 with slight modifications. Briefly, lipids were resuspended in 225 L of water. For total or free cholesterol measurements, 10 to 50 L per well was loaded on a 96-well plate together with a set of known cholesterol standards (0 -25 g). Total cholesterol values were obtained at 450 nm with the use of 200 L per well of the Infinity (Thermo Fisher Scientific) reagent, and free cholesterol values were determined at 550 nm with the use of 200 L per well of the free cholesterol E (Wako) reagent. CE/aorta values were determined as total cholesterol/aortaϪfree cholesterol/aorta.
Histological Quantification of Plaques
After perfusion-fixation, the upper part of the heart was separated from the ascending aorta, further fixed overnight in 4% paraformaldehyde in PBS, and embedded in paraffin. From the beginning of the valves to the aortic root (Ϸ420 m), 6 slices were analyzed (1 every 70 m) for determination of plaque area after Verhoeff/van Gieson staining. Plaques were manually outlined by an observer blinded for mouse genotypes with the use of ImageJ Software after adjustment for pixel size. Neighboring sections stained with Masson's trichrome were selected for publication.
Statistical Analysis
MeanϮSD values are presented except for ultrasound biomicroscopy, for which meanϮSEM values are shown. Two-tailed Student t tests rather than ANOVA tests were performed to determine P values because our ultimate goal was to compare KO versus WT mice and Tg versus WT mice.
Results
PCSK9 Deficiency Protects Mice Fed a Western Diet From Atherosclerosis
C57BL/6 mice expressing null (KO), normal (WT), or high (Tg) hepatic PCSK9 levels have been described previously. 27 In the present study, their plasma and liver were further analyzed by PCSK9 enzyme-linked immunosorbent assay, quantitative polymerase chain reaction, immunoblotting, and immunofluorescence ( Figure I in the online-only Data Supplement). Compared with WT mice, Tg mice have Ͼ100 times increased hepatic PCSK9 mRNA levels, 9-fold more circulating total PCSK9, undetectable cell surface LDLR in liver sections, and a 77% reduction in total liver LDLR protein. To assess the role of PCSK9 in atherogenesis, we first rendered these mice moderately dyslipidemic by feeding them a Western diet enriched in cholesterol, sugar, and fat (see Methods). KO mice fed a Western diet for 12 months, compared with WT mice fed the same diet, had a 35% reduction in plasma cholesterol levels associated with lower LDL-C levels ( Figure 1A and 1B) . KO mice also exhibited a 74% reduction in aortic CE ( Figure 1C ) to reach the CE levels usually observed in mice fed a chow diet (not shown), suggesting that the absence of PCSK9 abolished the dietinduced aortic CE accumulation. As reported previously, 32 WT mice fed a Western diet exhibited no detectable lesions by en face preparation ( Figure 1D ), histological analysis ( Figure 1E and Figure IIIA in the online-only Data Supplement), and ultrasound biomicroscopy (Figure 2A ). In contrast, Tg mice fed a Western diet for 12 months exhibited a marked increase in plasma cholesterol (ϩ80%; Figure 1A ) and aortic CE (ϩ230%; Figure 1C ). They were also the only mice that developed visible lesions, as assessed by en face preparation ( Figure 1D ), histological analysis ( Figure 1E and Figure IIIA in the online-only Data Supplement), and ultrasound biomicroscopy (Figure 2A ). Therefore, a direct relationship was observed between PCSK9 expression levels and aortic CE accumulation in mice fed a Western diet for 12 months. However, a potentially beneficial effect of the absence of PCSK9 on the development of advanced lesions could not be assessed with this approach.
PCSK9 Deficiency Protects ApoE-Deficient Mice From Atherosclerosis
The effect of PCSK9 on atherosclerosis was next examined in apoE-deficient mice known to spontaneously develop advanced lesions, even when fed a regular diet. 32, 33 ApoEdeficient mice expressing either no PCSK9 (KO/e; ie, Pcsk9 Ϫ/Ϫ Apoe Ϫ/Ϫ ), normal levels of PCSK9 (WT/e; ie, Pcsk9 ϩ/ϩ Apoe Ϫ/Ϫ ), or high levels of murine PCSK9 [Tg/e; ie, Tg(Pcsk9) ϩ/0 Apoe Ϫ/Ϫ ] were fed a regular diet for 6 months, and their LDLR and PCSK9 levels were characterized ( Figure I in the online-only Data Supplement). Different from WT mice fed a Western diet ( Figure 1B) , Apoe Ϫ/Ϫ mice exhibited a huge accumulation of VLDL remnants and LDL ( Figure 3B ), as expected from the known key role of apoE in mediating lipoprotein binding to receptors. 33 Possibly because of a dominant effect of apoE deficiency, plasma cholesterol levels were not significantly affected by the loss or overexpression of PCSK9 ( Figure 3A) . However, the aortic CE content was reduced by 39% in KO/e mice and increased by 137% in Tg/e mice ( Figure 3C ). Moreover, the latter mice exhibited a highly significant 207% increase of the average plaque size ( Figure 3E ). En face preparations of aortas ( Figure 3D ) showed more plaques in Tg/e mice. With the use of ultrasound biomicroscopy, no differences were detected between genotypes at the level of the root and ascending aorta, but a reliable 44% increase of IMT in the brachiocephalic artery was observed in Tg/e mice ( Figure  2B ). Although KO/e and Tg/e plasma cholesterol levels were not significantly different from those of WT/e mice ( Figure  3A) , a trend for lower intermediate-density lipoprotein/ LDL-C levels was observed in KO/e mice and an opposite trend for higher intermediate-density lipoprotein/LDL-C levels in Tg/e mice ( Figure 3B ), consistent with the known ability of PCSK9 to trigger LDLR degradation.
Effect of Age, Gender, and Diet in the ApoE-Deficient Background
Groups of KO/e, WT/e, and Tg/e mice were also fed a regular diet for 3 and 12 months. Three months after weaning, aortic CE was not markedly different between genotypes. After 12 months, however, aortic CE contents were Ϸ4-fold higher than those obtained after 6 months (Figure 4) , showing an exponential accumulation with time in all genotypes. Importantly, the degree of protection due to the absence of PCSK9 (32% versus 39% after 6 months; KO/e) remained in the same range, as well as the degree of exacerbation due to PCSK9 overexpression (167% versus 137% after 6 months; Tg/e). Analysis of groups of female mice fed a regular diet for 6 months revealed results similar to those observed in groups of males ( Figure IV in the online-only Data Supplement), showing that the proatherogenic effect of PCSK9 is not sex dependent. Finally, apoE-deficient mice were also fed a Western diet for 6 months, which caused the approximate doubling of plasma cholesterol values in all genotypes (not shown). KO/e mice were still protected from aortic CE accumulation (Ϫ19%), and their IMT was significantly re- duced at the level of the aortic valves (Ϫ25%), root (Ϫ18%), and ascending aorta (Ϫ9%) in KO/e mice ( Figure V in the online-only Data Supplement). However, no significant decrease of the plaque size was observed. Conversely, Tg/e mice had higher CE contents (ϩ50%) and plaque size (ϩ28%) and significantly higher IMT at the level of ascending aorta (ϩ19%) and brachiocephalic artery (ϩ40%). Altogether, our results suggest that the absence of PCSK9 protects apoE-deficient mice against atherosclerosis in both males and females, even when fed a Western diet.
PCSK9 Regulates Circulating Cholesterol and Aortic CE Accumulation via the LDLR
PCSK9 regulates LDLR 10 and VLDLR levels in vivo 18 and may affect other targets. To evaluate the role of PCSK9 in atherogenesis in the absence of the LDLR, LDLR-deficient mice lacking PCSK9 (KO/L; Pcsk9 Ϫ/Ϫ Ldlr Ϫ/Ϫ ) or expressing normal (WT/L; Pcsk9 ϩ/ϩ Ldlr Ϫ/Ϫ ) or high [Tg/L; Tg-(Pcsk9) ϩ/0 Ldlr Ϫ/Ϫ ] levels of murine PCSK9 were fed a Western diet for 3 months. The 3 lines did not significantly differ in plasma cholesterol, FPLC profiles, CE, en face plaque accumulation, plaque size ( Figure 5 ), and IMT ( Figure  2C) . These results indicate that PCSK9 exerts its effect on atherosclerosis mainly via the LDLR.
Discussion
In the present study, we compared the effects of the inactivation of PCSK9 versus its overexpression in the liver on the development of atherosclerosis in mice. We showed for the first time that the absence of PCSK9 protects WT and apoE-deficient mice from atherosclerosis, whereas PCSK9 overexpression results in stronger atherosclerotic phenotypes. Our data are in agreement with the reported 88% lower risk of developing cardiovascular complications over a 15-year period in individuals lacking 1 functional PCSK9 allele, 34 as well as with the reported atherogenic effect of human PCSK9-D374Y overexpression in mice. 35 In our study, atherosclerosis was tracked by 3 different but complementary techniques: (1) histological determination of plaque size at the level of the aortic valves and root; (2) ultrasound biomicroscopy at the level of aortic valves, root, ascending aorta, and brachiocephalic artery; and (3) CE accumulation in the whole aorta. Some discrepancies were observed between techniques and across the various models of mice used here. Those are mainly due to the specific regions examined and to the inherent sensitivity of each technique. Although histological analysis is a direct assessment, it is restricted to the aortic valves and root and did not allow detection of low levels of lipid accumulation in the remainder of the aorta ( Figure 1E ). Ultrasound biomicros- /e) PCSK9 levels were fed a normal diet for 3, 6, or 12 months from weaning (at Ϸ1 month of age) to euthanasia at 4, 7, or 13 months of age, respectively. Cholesteryl ester (CE) contents (meanϮSD) of aortas were determined (nϭ10 -12 mice per point). Note that data at 7 months correspond to those presented in Figure 3C . Symbols and error bars represent meanϪSD; by comparison with WT/e values, P (*PՅ0.05; ***PՅ0.001) was obtained with a 2-tailed Student t test. Least squares fit exponential curves were obtained with the use of GraphPad Prism Software (version 5.04); r 2 ϭ0.71, 0.69, and 0.78 for KO/e, WT/e, and Tg/e curves, respectively. copy, although noninvasive and rapid, did not detect subtle changes that were seen by CE determination (Figure 2B versus Figure 3C ). In contrast, despite requiring special dissection skills and patience, the determination of whole aortic CE contents was the most reliable assessment of the progression of atherosclerosis of the whole aorta, from early to late stages of plaque development, as observed by Véniant et al. 36 In mice exhibiting a WT background (Figure 1) and fed a 12-month Western diet, the absence or overexpression of PCSK9 has a strong impact on LDL accumulation (Ϫ35% and ϩ80%, respectively) and aortic CE levels (Ϫ74% and ϩ230%, respectively). In addition, in this model that does not develop plaques spontaneously, PCSK9 overexpression resulted in abundant plaques (Ϸ2 mm 2 ) and significantly increased IMTs (Figure 2A) .
In apoE-deficient mice fed a 6-month regular diet ( Figure  3) , the absence or overexpression of PCSK9 had a lower but still measurable impact on CE accumulation, with Ϫ39% and ϩ137% changes, respectively. Tg/e plaque size increased by 207%, whereas WT/e and KO/e plaque size did not significantly differ (0.4 -0.5 mm 2 ). The method may not be sensitive enough to accurately detect small variations among samples at this level of plaque development. Aortic CE values seem more sensitive, but they may not reflect the extent of plaque formation across models. Indeed, although WT mice accumulated 5 g of aortic CE without any detectable plaque ( Figure 1C and 1E) , a 3-g accumulation in WT/e mice (twice younger and fed a regular instead of a Western diet) coincided with the presence of plaques ( Figure 3C and 3E) . ApoE deficiency thus favors the development of atherosclerotic plaques at lower CE levels.
In the apoE-deficient model, VLDL-C and LDL-C levels seem to poorly predict the development of atherosclerosis because they differed only slightly between KO/e, WT/e, and Tg/e mice. It is still unclear whether the slightly higher LDL-C levels seen in Tg/e FPLC profiles are directly responsible for the 3-fold increase in Tg/e plaque size.
The clearly attenuated atherosclerotic phenotypes observed in KO and KO/e mice suggest that loss of PCSK9 may be even more protective against atherosclerosis in humans. Indeed, (1) only 30% of the circulating cholesterol is associated with LDL-C in mice versus 70% in humans; and (2) only 30% (versus 100% in human) of apolipoprotein B-containing lipoproteins secreted from mouse liver bind the LDLR as they carry apolipoprotein B 100 . Patients exhibiting a functional defect in apoE (type III hyperlipidemia) should also benefit from PCSK9 inhibitors.
Finally, to determine to which extent the atherogenic properties of PCSK9 were LDLR dependent, we analyzed mice exhibiting a LDLR-deficient background and fed a 3-month Western diet ( Figure 5 ). The absence or overexpression of PCSK9 had no significant impact on circulating cholesterol, FPLC profiles, aortic CE levels, or plaque size (Ϸ1 mm 2 ), suggesting that all of these parameters, and thus PCSK9 atherogenic properties, are essentially LDLR dependent. Clinically, these data suggest that patients with autosomal dominant hypercholesterolemia having no functional LDLR should not respond to a PCSK9 inhibitor.
In this study, we noted that our Tg mice that express high levels of PCSK9 18, 27 and exhibit low LDLR protein levels in the liver 27 ( Figure IB in the online-only Data Supplement) were by far less sensitive to atherosclerosis than LDLRdeficient mice (WT/L or Ldlr Ϫ/Ϫ ; Figure VI in the onlineonly Data Supplement). The LDLR fraction resistant to PCSK9 in Tg mice seems thus to play a key role in attenuating the atherosclerotic phenotypes. Because PCSK9 mainly exerts its effect on the LDLR either in a post-Golgi compartment or at the cell surface, 37, 38 this fraction, which is likely intracellular, could be sufficient to reduce VLDL secretion via intracellular apolipoprotein B degradation. 39, 40 Moreover, extrahepatic LDLR, which represents Ϸ30% of the whole-body LDLR, 41 may be less sensitive than hepatic LDLR to circulating PCSK9 42, 43 and contribute to VLDL and LDL uptake in Tg but not in Ldlr Ϫ/Ϫ mice.
Over the last few years, it became clear that PCSK9 is a promising and likely safe target to treat hypercholesterolemia and prevent coronary artery disease. 37 Because of its effect on VLDLR, PCSK9 inhibition could also affect the treatment of mixed dyslipidemias associated with the metabolic syndrome and diabetes mellitus. It may incidentally reduce vascular exposure to postprandial triglyceride-rich lipoproteins and prevent hepatic steatosis, as suggested from mouse studies. 18 Our study demonstrated that a life-long reduction in LDL-C in mice is safe and protects against atherosclerosis. In view of the selectivity of action of PCSK9 on LDLR in the liver 7, 27 and possibly in the small intestine, 7 it is expected that drugs that would target PCSK9 will exhibit fewer side effects that those related to statins. Various strategies were proposed to inhibit the function and/or levels of PCSK9, including mRNA knockdown approaches 44, 45 or passive immunization with the use of monoclonal antibodies that inhibit binding of PCSK9 to the LDLR. 46 All of these approaches are now being tested in clinical trials 47 (http://www.clinicaltrials.gov/ct2/ results?termϭPCSK9), and in 2012-2013 we should know their efficacy and safety profiles. With the rapid pace of discoveries in the field, it is hoped that within a few years lead molecules reducing the level or activity of PCSK9 will be uncovered and that these will find their way into the clinic to help patients suffering from dyslipidemia and atherosclerosis.
